Description

LORBRENA (lorlatinib)

Targeting ALK+ Metastatic Non-Small Cell Lung Cancer

LORBRENA is an advanced targeted therapy designed for adults diagnosed with ALK-positive metastatic non-small cell lung cancer (NSCLC). Developed to address specific genetic alterations that drive cancer growth, LORBRENA helps patients and healthcare professionals take a more personalized approach to treatment.

Why LORBRENA?

LORBRENA was specifically developed to target abnormalities in the anaplastic lymphoma kinase (ALK) gene. By inhibiting ALK-driven cancer activity, LORBRENA may help slow disease progression and support long-term treatment goals.

Key Benefits

• Once-daily oral treatment
• Designed to target ALK-positive NSCLC
• Engineered to penetrate the blood-brain barrier
• Supported by clinical research in patients with metastatic disease
• Personalized treatment approach based on genetic testing

Understanding ALK+ NSCLC

Approximately a small percentage of non-small cell lung cancer cases are driven by ALK gene alterations. Identifying these genetic changes through biomarker testing can help determine whether targeted treatment options such as LORBRENA may be appropriate.

The Importance of Biomarker Testing

Before treatment begins, healthcare providers perform testing to confirm the presence of ALK-positive disease. This testing helps ensure patients receive therapies tailored to the genetic characteristics of their cancer.

Patient Support Resources

Managing cancer treatment involves more than medication alone. Patients may have access to:

• Treatment education materials
• Financial assistance programs
• Ongoing support resources
• Healthcare team guidance throughout treatment

Talk to Your Healthcare Provider

Only a qualified healthcare professional can determine whether LORBRENA is appropriate for your specific condition. Discuss your diagnosis, treatment goals, and medical history with your healthcare provider.

Safety Information

LORBRENA may cause serious side effects. Patients should review the full prescribing information and discuss potential risks and benefits with their healthcare provider before starting treatment.

For complete prescribing information, consult your healthcare professional.